Navigation Links
MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer
Date:3/28/2008

ORCHARD PARK, NY, March 28 /PRNewswire-FirstCall/ -- MINRAD International, Inc. (Amex: BUF) today announced its Board of Directors approved the appointment of David T. DiGiacinto as President and Chief Operating Officer, effective April 1, 2008, when he will take over the day-to-day operations of the Company. Mr. DiGiacinto's appointment is the first step in a transition in which he will become Chief Executive Officer of the Company beginning on January 1, 2009. William H. Burns, Jr. will continue to serve as Chief Executive Officer through the end of the year and has agreed to continue serving as Chairman of the Board of Directors until the Company's 2009 annual meeting, on terms and conditions which have not been finalized but which are expected to be determined within the next two months. It is anticipated he will also continue to serve on the Scientific Advisory Board of the Company during the transition and after his term as Chairman expires.

Mr. DiGiacinto is joining Minrad from Spencer Trask & Co., a private equity firm based in New York City, where he served as a Senior Managing Director. Spencer Trask invests primarily in early stage companies with technologies in a variety of market segments. Mr. DiGiacinto was mainly focused on Healthcare, Specialty Chemicals, Nutritionals and Food Ingredients. Spencer Trask Specialty Group LLC, an affiliate of Spencer Trask & Co., was an early stage investor in Minrad, Inc. in 1999 and provided the primary financing to Minrad through 2002. Mr. DiGiacinto currently serves as an advisor to the Company and has been a member of the Board of Directors since 2004. He will continue to serve as a director of the Company after assuming his new position.

Prior to joining Spencer Trask in 2000, Mr. DiGiacinto spent 18 years at Pfizer, Inc. While with Pfizer, he performed several operational and management functions both in the U.S. and Internationally. These included serving as its Director of Marketing in charge of a variety of products, including bulk antibiotics; profit and loss responsibility over its Latin American Division; and management of it's Worldwide Brewery and Dairy Division, which included both manufacturing and packaging sites. Mr. DiGiacinto is a graduate of the U.S. Military Academy at West Point. After graduation, he spent nearly seven years serving as a pilot in the U.S. Air Force. After leaving the service, he flew for a year commercially before joining Pfizer.

In order to ensure an orderly transition and to assist Mr. DiGiacinto in his new role, William H. Burns, Jr. will continue to serve as Chief Executive Officer through the end of the year. In addition to assisting Mr. DiGiacinto in his transition to Chief Executive Officer, Mr. Burns will continue to be responsible for strategic initiatives of the Company, including the expansion of its international operations, its conscious sedation program and implementing the strategy to secure the anesthesia business of the group purchasing organizations in the United States. Mr. DiGiacinto stated "Bill Burns and I have worked together over the past eight years to help Minrad move from an early stage company to a company publicly traded on the American Stock Exchange. I am excited to begin this new role at Minrad, and look forward to our working together over the next year to continue the company's development.

About the Company

MINRAD International, Inc. is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company's website, http://www.minrad.com.

The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International's limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading "Risk Factors" of Minrad International's Form 10-KSB, filed with the Securities and Exchange Commission on March 29, 2007. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

Contact: Charles T. Trego, Jr.; Executive V.P. and CFO

ctrego@minrad.com

(716) 855-1068

http://www.minrad.com


'/>"/>
SOURCE MINRAD International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
2. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
3. Corium International, Inc. Announces Appointment of Phyllis Gardner, M.D. and Daniel G. Welch to Board
4. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
6. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
7. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one ... been named Fellows of the Society this year, the Fellows Committee has announced. ... fields of optics, photonics, and imaging as well as their service to the ...
(Date:2/22/2017)... 2017 Scientists propose in Nature ... in Gaucher and maybe other lysosomal storage diseases as ... than current therapies. An international research team ... which also included investigators from the University of Lübeck ... Feb. 22. The study was conducted in mouse models ...
(Date:2/22/2017)... -- Dublin - Research and ... Protection (Bio-Pesticide) Market-By Type, By Application, By End User, By Region, ... ... Crop Protection Market is forecasted to grow at a CAGR of ... or biological crop protection market is driven by the surging demand ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 ... announced today expansion of its translational research program ... through establishment of laboratory facilities in San Diego.  ... San Diego BioLabs facility, a biotechnology incubator sponsored ... Sanofi. In November 2016, the Company ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):